Tabersonine enhances cisplatin sensitivity by modulating Aurora kinase A and suppressing epithelial–mesenchymal transition in triple-negative breast cancer

Xi Chena Department of Pharmacy, Xiangya Hospital, Central South University, Changsha, Hunan, ChinaView further author information

Yuanliang Yana Department of Pharmacy, Xiangya Hospital, Central South University, Changsha, Hunan, ChinaView further author information

Yuanhong Liua Department of Pharmacy, Xiangya Hospital, Central South University, Changsha, Hunan, ChinaView further author information

Qiaoli Yia Department of Pharmacy, Xiangya Hospital, Central South University, Changsha, Hunan, ChinaView further author information

Zhijie Xub Department of Pathology, Xiangya Hospital, Central South University, Changsha, Hunan, China;c National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, Hunan, ChinaCorrespondence[email protected]
View further author information

Tabersonine enhances cisplatin sensitivity by modulating Aurora kinase A and suppressing epithelial–mesenchymal transition in triple-negative breast cancer

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Tabersonine enhances cisplatin sensitivity by modulating Aurora kinase A and suppressing epithelial–mesenchymal transition in triple-negative breast cancer

Citations (0)

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date